Introduction: Despite the demonstrated efficacy of hydroxyurea therapy, children with sickle cell anaemia in the UK are preferentially managed with supportive care or transfusion. Hydroxyurea is reserved for children with severe disease phenotype. This is in contrast to North America and other countries where hydroxyurea is widely used for children of all clinical phenotypes. The conservative UK practice may in part be due to concerns about toxicity, in particular marrow suppression with high doses, and growth in children.
INTRODUCTION
In children with sickle cell anaemia (SCA), hydroxyurea therapy is effective at elevating foetal haemoglobin (HbF) and reducing the frequency of painful sickle crises. [1] [2] [3] Despite the demonstrated efficacy of hydroxyurea therapy, children with SCA are preferentially managed with supportive care or transfusion at UK treatment centres. Current UK clinical guidance is supportive care and prophylactic antibiotics for all children, and transfusion in instances of acute and chronic complications such as acute anaemia, acute chest syndrome, acute neurological deficit, stroke prevention and organ failure. Hydroxyurea is restricted to those with severe phenotype. Current guidelines recommend that it is considered only in patients who experience recurrent episodes Abbreviations: FBC, full blood count; Hb, haemoglobin; HbF, foetal haemoglobin; MTD, maximum tolerated dose; SCA, sickle cell anaemia; TCD, transcranial Doppler This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. of acute pain (more than three hospitalisations in the previous 12 months or symptomatic in the community) or who have experienced two or more episodes of acute chest syndrome. 4 Referral to a specialist centre is required for hydroxyurea commencement and it is recommended that the patient and parents or carers have two separate documented discussions with treating clinicians to include side effects such as subfertility, cytopenias and the possible risk of leukaemia or other malignancies. 4 The effect of such guidance is that few children with SCA in the UK benefit from hydroxyurea therapy. Currently 1.9% of UK patients with SCA < 5 years of age receive hydroxyurea, and 11.3% of 5-17 year old UK SCA patients receive hydroxyurea. 5 Reluctance to incorporate hydroxyurea into first-line treatment in the UK relates in part to concerns over long-term safety and negative effects on growth, combined with a lack of awareness of potential treatment benefits. Since publication of the current UK Standards and Guidance for Clinical Care (2010), much more evidence as to the safety and efficacy of hydroxyurea therapy has become available. 2, [6] [7] [8] [9] [10] In the United States, it is now recommended that all children with sickle cell anaemia be offered hydroxyurea therapy from 9 months of age. 11 Concerns over potential negative effects on growth were addressed initially in the 1999 HUG-KIDS phase I/II trial. Fifty-two severely affected children aged 5-15 years were treated to maximum tolerated dose (MTD) with a median dose of 30 mg/kg/day hydroxyurea for 1 year and no child experienced growth failure. 12 Following on from this, the HUSOFT extension study examined the effects of longer term treatment (up to 6 years) on 21 very young children, and reported that females maintained average growth rates and males increased average growth rates during hydroxyurea therapy. 13 Since hydroxyurea inactivates the enzyme ribonucleoside diphosphate reductase, 14 it impairs both DNA replication and repair. This gives rise to concerns as to its carcinogenic and teratogenic potential.
So far, two follow-up studies have investigated the risks and benefits of very long-term use in adults. 15, 16 The Multicentre Study of Hydroxyurea in Sickle Cell Anaemia trial had a 17.5 year follow up and some participants had received greater than 15 years cumulative exposure.
This study found that there was no increase in neoplasia by exposure to hydroxyurea. 15 Another single centre trial, where 131 adults were followed for up to 17 years, also reported that no cases of carcinogenesis occurred. 16 Importantly, both of these studies reported significantly improved survival in hydroxyurea-treated patients. 15, 16 More recently, investigators in the BABY-HUG phase III clinical trial sought to measure acquired genomic damage in infants, as a measure of carcinogenic potential. Karyotype analysis (to investigate chromosome/chromatid breaks), illegitimate variable diversity joining recombination events and micronucleated reticulocytes were monitored and there were no differences between hydroxyurea-and placebo-treated patients. 10 Since the reporting of the BABY-HUG trial results, we have offered hydroxyurea as a first-line treatment to all children over 9 months of age with SCA at this UK centre. Here, we sought to review the benefits of hydroxyurea therapy in a UK paediatric cohort and to determine the effect of dose escalation and adherence to therapy in terms of improvement in haematological parameters and hospital admissions.
METHODS
All children over 9 months of age were offered hydroxyurea therapy and no selection for disease severity was made. Baseline investigations were performed to confirm the absence of anaemia (haemoglobin [Hb] > 50 g/l), absence of cytopenias (neutrophils >1.0 × 10 9 /l, platelets >100 × 10 9 /l, reticulocytes >40 × 10 9 /l) and absence of severe hepatic or renal impairment (estimated glomerular filtration rate >30 ml/min/1.73 m 2 ). Patients were not considered for hydroxyurea therapy if they had known hypersensitivity to hydroxyurea, were pregnant, had active hepatitis, showed any signs of myelosuppression or were receiving anti-retroviral therapy.
Treatment commenced at 15 mg/kg/day to be increased over the following 12 months to MTD or 35 mg/kg/day, whichever was achieved first. MTD was defined by haematological toxicity as the maximum dose where no myelosuppression was induced. On commencement of therapy, full blood counts (FBCs) were monitored fortnightly for the first 4 weeks and then at 4 weekly intervals. Clinical assessment was made monthly and included frequency and severity of crises, complications of sickle cell disorders, compliance with treatment, adverse events, height and weight measurements and laboratory monitoring of hepatic and renal function, reticulocytes, FBC and Hb electrophoresis. Dose was increased by 5 mg/kg/day every 8 weeks, provided that no marrow toxicity was observed (defined as neutrophil count <0.75 × 10 9 /l or platelet count <75 × 10 9 /l or reticulocyte count <40 × 10 9 /l). FBCs were monitored fortnightly following dose increases for 4 weeks, and then at 4 weekly intervals.
RESULTS
Ninety-five percent of children and parents or carers offered hydroxyurea consented following discussion of current evidence in relation to side effects and benefits of treatment (n = 37). Hydrea in 500 mg capsule or liquid formulation was prescribed. The mean age at start of therapy in our patients was 7 years (range 1-15), 34 patients were HbSS, two were HbS 0 thalassemia and one was HbSD. The mean dose achieved in patients who had been on therapy for more than 6 months was 28.5 mg/kg/day.
Significant improvements were recorded in haematological parameters post-hydroxyurea therapy; Hb increased to 92.0 g/l from 80.6 g/l, HbF increased to 26.35% from 9.90%, MCV increased to 91.06 from 77.49, reticulocytes decreased to 127.6 × 10 9 /l from 335.4 × 10 9 /l and neutrophils decreased to 3.95 × 10 9 /l from 6.37 × 10 9 /l (n = 37; P < 0.001 by paired t-test for each parameter; Supplementary Fig. S1 ).
A significant reduction in platelets was also recorded in our patients (to 263.3 × 10 9 /l from 352.4 × 10 9 /l; P = 0.0007; Supplementary Fig. S1 ).
At the time of review, 16 patients were receiving <26 mg/kg/day hydroxyurea and 21 patients were receiving ≥26 mg/kg/day. Comparative analysis of patients receiving <26 and ≥26 mg/kg/day indicated that dose had a significant effect on some parameters. Hb levels were increased post-hydroxyurea therapy irrespective of dose achieved (Fig. 1A) , whereas HbF level, MCV and reticulocyte count were further improved in patients receiving ≥26 mg/kg/day (Figs. 1B-1D ). Neutrophil and platelet counts were only significantly reduced in patients receiving ≥26 mg/kg/day (Figs. 1E and 1F ). Patient age versus dose achieved is shown in Figure 1G .
Haemolysis was better controlled in patients receiving ≥26 mg/kg/ day. Bilirubin and lactate dehydrogenase (LDH) were significantly lower in patients receiving ≥26 mg/kg/day ( Figs. 2A and 2B ). Concurrent monitoring of alanine amino transferase (ALT) and aspartate amino transferase (AST) showed no evidence of liver toxicity in any patient, although AST was significantly reduced in patients receiving ≥26 mg/kg/day (Figs. 2C and 2D) . Serum creatinine and urea were monitored continuously and remained within age appropriate reference range for all patients. Adherence to therapy was reported by the patient and parent or carer at each clinic visit. We identified 10 patients with poor adherence to therapy based on patient/parent/carer admission and confirmed that they had not collected prescriptions regularly enough to maintain prescribed daily dosing. Comparative analysis between these patients with poor adherence, and all other patients who were considered to have good adherence (based on patient/parent/carer reporting), indicates that improvement in haematological parameters is dependent on good adherence to therapy (Fig. 3) . Hb and HbF levels were significantly higher in patients with good adherence (Figs. 3A and 3B ). As would be expected, MCV was significantly higher with good adherence (Fig. 3C) , and reticulocyte and neutrophil counts were significantly lower (Figs. 3D and 3E ). Adherence had no significant effect on platelet count (Fig. 3F) Adherence to therapy also had a significant impact on the number of hospitalisations experienced by patients. Twenty-seven hospitalisations totalling 126 admission days were recorded for the 10 patients with poor adherence compared to nine hospitalisations totalling 49 admission days in the 27 patients with good adherence (P < 0.0001 by 2 test; 24-month follow up). Height and weight were monitored continuously for all patients and growth rates were maintained in all children irrespective of dose achieved or adherence to therapy (Fig. 4) .
F I G U R E 4
Growth rates in children following hydroxyurea therapy. Height (A) and weight (B) were maintained in children treated with hydroxyurea. Arrow indicates commencement of hydroxyurea therapy. Data shown is height for age (A) and weight for age (B) z-score calculated using CDC growth chart 19 
DISCUSSION
Our data demonstrate the significant improvements in haematological parameters that can be achieved with hydroxyurea therapy in UK paediatric patients with SCA. All children in this study had previously been managed at UK treatment centres with supportive care or transfusions. Importantly, hydroxyurea resulted in significant improvements in Hb, HbF, MCV, reticulocyte and neutrophil count, which were apparent within 6 months of therapy commencement. Our data indicate that dose escalation is required to maximise beneficial effects, par- The UK paediatric patient cohort in this study benefited from hydroxyurea therapy as expected based on previous reports of hydroxyurea use in SCA. 2, 12, 13, 18 As such, we believe it is now time to address the barriers to therapy that exist within the UK. No negative effects on growth were observed in this study and the only treatment-related toxicities encountered were cytopenias, most frequently mild cytopenias that resolved without the need for dose reduction.
We considered neutrophil count <0.75 × 10 9 /l, platelet count < 75 × 10 9 /l or reticulocyte count < 40 × 10 9 /l clinically significant toxicities. Nine of the 37 children treated experienced significant cytopenia, totalling 22 separate episodes. Three children experienced a single episode (two reticulocytopenia and one thrombocytopenia) while being clinically well. Laboratory monitoring was increased to weekly and counts recovered within 2 weeks (thrombocytopenia) and 6 weeks (reticulocytopenia) without the need for dose adjustment. One child experienced two episodes of reticulocytopenia 8 months apart while being clinically well, and one child experienced two episodes of thrombocytopenia 15 months apart while being clinically well. Both children were managed with increased laboratory monitoring and counts recovered within 2 weeks (thrombocytopenia) or 3 weeks (reticulocytopenia) without the need for dose adjustment. Three children experienced cytopenias following dose increase or alongside falling Hb or neutrophil count, which required dose adjustment (six thrombocytopenia and one reticulocytopenia). Hydroxyurea therapy was stopped and laboratory monitoring increased to weekly. Hydroxyurea was re-commenced following recovery of counts, which occurred within 1-3 weeks. Therapy was recommenced at the same dose for children receiving <20 mg/kg/day or at a reduced dose for children receiving >20 mg/kg/day. One child with severe phenotype experienced seven episodes of cytopenia over 21 months (four neutropenia and three reticulocytopenia). Each cytopenia was managed with increased laboratory monitoring and resolved without the need for dose reduction. We persisted with hydroxyurea therapy for this patient as significant improvement in clinical features were seen, including reduced crisis, return of conditional TCD to normal and increase in HbF from 7.0 to 32.7%. In our experience, isolated cytopenias are best managed initially with increased laboratory monitoring (weekly) while maintaining dose in clinically well children. Dose reduction or therapy cessation should be considered when an isolated cytopenia is persistent or deteriorates, or if more than one haematological parameter is affected.
While hydroxyurea therapy resulted in clinical improvement, in comparison to a supportive care approach, it also resulted in increased medication-related burden on patients and families. In this respect, when children are established on a stable dose it may be possible to reduce monitoring to bimonthly to counteract some of this additional burden. 20 Achieving accurate dosing in children prescribed 500 mg capsules frequently required an "asymmetric" daily dosing schedule to achieve a desired weekly intake, and this adds an additional layer of complexity to daily administration. However, these issues were overcome in our patients and their families who were motivated by tangible treatment benefits such as improvements in laboratory values.
Currently, the UK National Haemoglobinopathy Registry shows only 9.5% of all UK patients with SCA <18 years of age receive hydroxyurea therapy. 5 In the absence of substantive evidence to contradict safety, we advocate the use of hydroxyurea as a diseasemodifying therapy for all UK children with SCA. Future UK clinical guidelines should place more focus on achievable benefits with hydroxyurea, and broaden the application to many more children.
